Mark Wheatley Selected Research

substance P (6-11)

1/2009

Targeting V1A-vasopressin receptors with [Arg6, D-Trp7,9, NmePhe8]-substance P (6-11) identifies a strategy to develop novel anti-cancer therapies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark Wheatley Research Topics

Disease

1	Disease Susceptibility (Diathesis) 01/2010
1	Hemorrhage 01/2010
1	Neoplasms (Cancer) 01/2009
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2009
1	Seizures (Absence Seizure) 12/2005
1	Pain (Aches) 12/2005

Drug/Important Bio-Agent (IBA)

2	LigandsIBA 01/2010 - 12/2005
1	Prostaglandin H2 Thromboxane A2 ReceptorsIBA 01/2010
1	substance P (6-11)IBA 01/2009
1	Arginine Vasopressin (Argipressin)IBA 01/2009
1	Gastrin-Releasing PeptideIBA 01/2009

Therapy/Procedure

1	Therapeutics 01/2009